Study Stopped
Insufficient recruitment
Radiofrequency Ablation Versus Stereotactic Radiotherapy in Colorectal Liver Metastases
RAS01
The International Liver Tumor Group RAS-trial Radiofrequency Ablation Versus Stereotactic Body Radiation Therapy for Colorectal Liver Metastases: A Randomized Trial
1 other identifier
interventional
300
2 countries
2
Brief Summary
This randomized clinical phase III trial is testing the efficacy of radiofrequency ablation (RFA) and stereotactic body radiotherapy (SBRT) in the treatment of colorectal carcinoma liver metastases. Primary end point is local progression free survival.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3
Started Sep 2010
Typical duration for phase_3
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2010
CompletedFirst Submitted
Initial submission to the registry
November 2, 2010
CompletedFirst Posted
Study publicly available on registry
November 3, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2014
CompletedMay 12, 2016
May 1, 2015
4.3 years
November 2, 2010
May 11, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Local progression-free survival
3 years
Secondary Outcomes (4)
Toxicity
3 years
Survival
3 years
Progression (local or distant)
3 years
Quality of life
3 years
Study Arms (2)
Stereotactic body radiation therapy
EXPERIMENTALColorectal liver metastases treated by SBRT
Radiofrequency ablation
ACTIVE COMPARATORColorectal liver metastases treated by RFA
Interventions
Patients are allocated to one of the two arms in a 1:1 randomization
Eligibility Criteria
You may qualify if:
- Adenocarcinoma of the colon or rectum
- Liver metastases
- Inoperable (technical or medical)
- metastases
- Maximum 40 mm in diameter
- Suitable for both therapies, RFA and SBRT
You may not qualify if:
- Uncontrolled extrahepatic disease and uncontrolled primary cancer
- Liver cirrhosis
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Aarhus University Hospital
Aarhus C, 8000, Denmark
Karolinska Institute, Huddinge
Stockholm, 141 86, Sweden
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Morten Høyer, MD PhD
Aarhus University Hospital
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 2, 2010
First Posted
November 3, 2010
Study Start
September 1, 2010
Primary Completion
December 1, 2014
Study Completion
December 1, 2014
Last Updated
May 12, 2016
Record last verified: 2015-05